Bechtold-Peters K, Chang S, Lennard AC, Mateffy J, Murphy M, Perry M, Roesti D, Singer DC, Wintzingerode FV, Yang H. Risk-based approach to setting sterile filtration microbial bioburden limits - Focus on biotech-derived products.
Eur J Pharm Biopharm 2024;
198:114151. [PMID:
38043622 DOI:
10.1016/j.ejpb.2023.11.016]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2023] [Revised: 11/15/2023] [Accepted: 11/18/2023] [Indexed: 12/05/2023]
Abstract
Holistic concepts should be applied that reduce risks prior to final bioburden testing and sterile filtration, based on enhanced process and product attribute understanding, which could be key to successful bioburden risk management. Key findings of this paper include.
Collapse